FDA Issues Draft Guidance on USP Pending Monograph Process

Drug Industry Daily
A A
The FDA offers advice to drug sponsors on how to revise an existing monograph or develop a new one, in a newly released draft guidance.

To View This Article:

Login

Subscribe To Drug Industry Daily